

Flerie's portfolio company Nanologica has received an important order from a new customer

Stockholm, 24 April, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media NLAB Saga® from a new customer in China.

The order for NLAB Saga® amounts to USD 180,000 and is expected to be delivered in the second quarter. The customer is a large pharmaceutical manufacturer and the order is for the evaluation of NLAB Saga® at production scale for use in the production of GLP-1 analogs, a rapidly growing area globally for the treatment of type 2 diabetes and obesity.

"This is very good news for Nanologica and an important step into the rapidly growing and strategically important GLP-1 segment. We look forward to following the company's continued development in China." says Mark Quick, Partner at Flerie.

Read Nanologica's full press release here: [nanologica-ab-receives-order-worth-usd-180-000-from-new-customer-in-china.pdf](#)

Flerie's holding in Nanologica amounts to 43%.

For more information:

Mark Quick

Email: ir@flerie.com

Attachments

[Flerie's portfolio company Nanologica has received an important order from a new customer](#)